Eosinophilic Esophagitis: EP 104GI Treatment Study

We are testing a new treatment called EP 104GI for adults with eosinophilic esophagitis. The study aims to evaluate its safety and effectiveness in reducing symptoms and improving esophageal health.

1-2 years 6-10 visits Safety phase (I)Efficacy phase (II)No Placebo Investigational Medicines InjectionAllergologyGastroenterology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Fluticasone Propionate

Fluticasone propionate is a corticosteroid substance that reduces inflammation in the airways, nose, or skin to relieve allergy and asthma symptoms.

Tetracosactide

Tetracosactide is a synthetic ACTH substance that stimulates the adrenal glands to produce cortisol, used to test adrenal function and treat adrenal insufficiency.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Ep-104gi

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Amsterdam UMC Stichting

Gastroenterology

Abcoude, Netherlands

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Gastroenterology

Rotterdam, Netherlands

Sponsor: Eupraxia Pharmaceuticals Inc.

Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.